CELESTIAL
Cabozantinib extended survival in previously treated liver cancer, including after two prior therapies.
OS 10.2 vs 8.0 months (HR 0.76); PFS 5.2 vs 1.9 months.
Setting
HCC after sorafenib (up to two prior lines): cabozantinib vs placebo
Phase
Phase 3
Sponsor
Exelixis
Registry
Headline result
OS 10.2 vs 8.0 months, HR 0.76.
Reported
2018
Enrolled
707
In plain words
What these results mean for people, not percentages
Overall survivalprimarysurvival endpoint
- Median 10.2 vs 8 months with Cabozantinib compared with Placebo; about 2.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 24 percent lower chance of the event at any given time (hazard ratio 0.76, likely range 0.63 to 0.92).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
Progression-free survivalsurrogate endpoint
- Median 5.2 vs 1.9 months with Cabozantinib compared with Placebo; about 3.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 56 percent lower chance of the event at any given time (hazard ratio 0.44).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
Be careful
- These results apply to the people the trial enrolled: HCC after sorafenib (up to two prior lines): cabozantinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
707 participants enrolled.
Overall survivalprimary
HR 0.76 (0.63–0.92) · p = 0.005
Cabozantinib
10.2 mo
Placebo
8 mo
Progression-free survival
HR 0.44
Cabozantinib
5.2 mo
Placebo
1.9 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Cabozantinib | 470 | 10.2 months | 0.76 (0.63–0.92) | 0.005 | — |
| Placebo | 237 | 8 months | ||||
| Progression-free survival | Cabozantinib | — | 5.2 months | 0.44 | — | — |
| Placebo | — | 1.9 months |
Pages like this
not linked directly; found by shared links- CompanyExelixis
Shares Cabozantinib, Hepatocellular carcinoma.
- PathwayThe angiogenic switch & tumour vessels
Shares Cabozantinib, Hepatocellular carcinoma.
- TargetMET
Shares Cabozantinib, Hepatocellular carcinoma.